Rhythm Pharmaceuticals' 84% year-over-year revenue growth and 39% analyst upside target reflect a high-conviction commercial ramp for setmelanotide, but single-product concentration and below-floor quality scores make this a speculative position requiring close monitoring.
Thesis pillars
- Setmelanotide Revenue Ramp→Stable
- Momentum Surge Signal↓Deteriorating
- Analyst Conviction Asymmetry→Stable
- +1 more pillar — see the Why tab for full reasoning
Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $102.10: Quality below floor (3.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.5/10 and A.R:R 2.3:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 14%; Below-average business quality; Negative price momentum.
Rhythm Pharmaceuticals markets IMCIVREE (setmelanotide) for rare MC4R pathway diseases including BBS and POMC/PCSK1/LEPR deficiencies, with approvals in the US, EU, UK, and Canada. Revenue comes from specialty drug sales across more than 25 countries; cumulative product revenue... Read more
Sell if holding. Engine safety override at $102.10: Quality below floor (3.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.5/10 and A.R:R 2.3:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 14%; Below-average business quality; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.5/10, moderate confidence.
Passes 5/8 gates (favorable risk/reward ratio, clean insider activity, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: speculative.
About Rhythm Pharmaceuticals, Inc.
About Rhythm Pharmaceuticals, Inc.
IMCIVREE (setmelanotide) became the first therapy approved for BBS and POMC/PCSK1/LEPR deficiency obesity when the FDA cleared it in 2020; Rhythm Pharmaceuticals has since secured authorization across more than 25 countries, generating approximately $422.5 million in cumulative product revenue through December 31, 2025. The company employed 414 people at February 1, 2026, and held $388.9 million in cash and short-term investments at year-end. An FDA decision on IMCIVREE for acquired hypothalamic obesity carried a PDUFA goal date of March 20, 2026.
Rhythm generates revenue from IMCIVREE sales through specialty pharmacy channels for an estimated 4,600 to 7,500 US patients in currently approved indications. The revenue interest financing agreement with HealthCare Royalty Management — fully drawn to $99.4 million net of issuance costs by September 2023 — carries tiered royalties of 11.5% on annual revenues up to $125 million, 7.5% between $125 million and $300 million, and 2.5% above $300 million, creating a persistent cash drag on gross receipts. Bivamelagon, licensed from LGC in January 2024, adds a low- to mid-single-digit royalty obligation on MC4R portfolio revenues starting in 2029. The company targets commercial expansion in Japan pending approval, with a new drug application planned following Phase 3 topline data from a 12-patient Japanese cohort expected in March 2026.
Show full overview
EMANATE, the Phase 3 basket trial testing setmelanotide across four genetically defined MC4R pathway diseases — heterozygous POMC/PCSK1 obesity, heterozygous LEPR obesity, SRC1 deficiency, and SH2B1 deficiency — was expected to deliver independent topline results from each substudy in March 2026. Each substudy is designed to support a separate NDA filing; an adverse safety finding in one cohort could trigger a clinical hold across the entire trial, exposing all four programs simultaneously. Bivamelagon completed a positive end-of-Phase-2 FDA meeting on February 26, 2026, partially diversifying the binary readout risk.
See also: Healthcare · Biotechnology
From Rhythm Pharmaceuticals, Inc.'s most recent 10-K filing, extracted June 11, 2026.
Recent developments
updated 2026-07-26Recent Developments — Rhythm Pharmaceuticals, Inc.
Latest news
- NEWS Rhythm Pharmaceuticals Announces That Results From Its Pivotal Phase 3 TRANSCEND Trial Evaluating Setmelanotide, A Melan — benzinga Jul 8, 2026 positive
- NEWS RBC Capital Maintains Outperform on Rhythm Pharmaceuticals, Raises Price Target to $141 — benzinga Jul 7, 2026 positive
- NEWS Canaccord Genuity Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $151 — benzinga Jun 16, 2026 positive
- NEWS Rhythm Pharmaceuticals Presents Data From Multiple Presentations At Endocrine Society's Annual Meeting — benzinga Jun 15, 2026 positive
- NEWS Why Is Rhythm Pharma Stock Jumping Today? — benzinga Jun 15, 2026 positive
Generated 2026-07-26T05:12:17Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductsetmelanotide10-K Item 1A: 'we have focused substantially all our efforts and financial resources on the research and development of setmelanotide'
Material Events(8-K, last 90d)
- 2026-04-03Item 5.02LOWKimberly J. Popovits elected as Class II non-employee director effective April 1, 2026, serving through 2028 annual meeting. Edward T. Mathers resigned from the Board effective April 1, 2026; no disagreement with company operations or practices cited.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers·1 ceiling hit
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Clinical-stage biotech: losses expected pre-commercialisation. Quality floor doesn't distinguish R&D investment from operational decay — components above tell the real story.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $102.10: Quality below floor (3.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.5/10 and A.R:R 2.3:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 14%; Below-average business quality; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $98.01. Score 5.5/10, moderate confidence.
Take-profit target: $120.37 (+17.9% upside). Prior stop was $98.01. Stop-loss: $98.01.
Concentration risk — Product: setmelanotide; Quality below floor (3.5 < 4.0); Value-trap signals (2/5): High leverage (D/E 3.6), Material insider selling (3 sells, 15.62% of cap).
Rhythm Pharmaceuticals, Inc. trades at a P/E of N/A (forward -138.5). TrendMatrix value score: 4.5/10. Verdict: Sell.
22 analysts cover RYTM with a consensus score of 4.3/5. Average price target: $138.
What does Rhythm Pharmaceuticals, Inc. do?Rhythm Pharmaceuticals markets IMCIVREE (setmelanotide) for rare MC4R pathway diseases including BBS and...
Rhythm Pharmaceuticals markets IMCIVREE (setmelanotide) for rare MC4R pathway diseases including BBS and POMC/PCSK1/LEPR deficiencies, with approvals in the US, EU, UK, and Canada. Revenue comes from specialty drug sales across more than 25 countries; cumulative product revenue reached approximately $422.5 million through December 31, 2025.